Mastoparan 7 (trifluoroacetate salt)
(Synonyms: Mas7) 目录号 : GC91846Mastoparan 7 is a G protein activator and derivative of the mast cell degranulating peptide mastoparan.
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Mastoparan 7 is a G protein activator and derivative of the mast cell degranulating peptide mastoparan.[1] It decreases the affinity of acetylcholine (ACh) to porcine brain muscarinic ACh receptors (mAChRs) when used at a concentration of 30 µM and induces GDP/GTP exchange by Gi in a concentration-dependent manner. Mastoparan 7 (1 µM) also induces activation of Gαo in, and increases dendritic spine density of, primary rat hippocampal neurons.[2] It induces contractions in isolated perfused rat tail arteries (EC50 = 44.1 nM).[3] Immunization with a vaccine against cocaine in combination with mastoparan 7 as an adjuvant increases hapten-specific serum IgG levels and decreases cocaine-induced locomotion in mice.[4]
References:
[1].Higashijima, T., Burnier, J., and Ross, E.M.Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activityJ. Biol. Chem.265(24)14176-14186(1990).
[2].Ramírez, V.T., Ramos-Fernández, E., and Inestrosa, N.C.The Gαo activator mastoparan-7 promotes dendritic spine formation in hippocampal neuronsNeural Plast.4258171(2016).
[3].Grześk, G., Malinowski, B., Grześk, E., et al.Direct regulation of vascular smooth muscle contraction by mastoparan-7Biomed. Rep.2(1)34-38(2014).
[4].St. John, A.L., Choi, H.W., Walker, Q.D., et al.Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacyNPJ Vaccines5(1)12(2020).
Cas No. | N/A | SDF | Download SDF |
别名 | Mas7 | ||
分子式 | C67H124N18O15•XCF3COOH | 分子量 | 1421.8 |
溶解度 | Water: Soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.7033 mL | 3.5167 mL | 7.0333 mL |
5 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL |
10 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。